Beiying Ding
Genentech
21 Papers
48 Citations
Beiying Ding is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Medicine. The author has an hindex of 8, co-authored 21 publications.
Chat about Author
Papers
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
Andrea Necchi,Richard W. Joseph,Yohann Loriot,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Daniel P. Petrylak,Christina Louise Derleth,Darren Tayama,Q. Zhu,Beiying Ding,Constanze Kaiser,Jonathan E. Rosenberg +11 more
TL;DR: Patients who continued atezolizumab beyond RECIST v1.1 progression derived prolonged clinical benefit without additional safety signals and remained an important challenge in the management of metastatic urothelial carcinoma.
254
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Riad Salem,Daneng Li,Nicolas Sommer,Sairy Hernandez,Wendy Verret,Beiying Ding,Riccardo Lencioni +6 more
TL;DR: The IMbrave150 trial as mentioned in this paper compared ATezolizumab + bevacizumabi (ATEZO/BEV) versus SOR (SOR) in patients with hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes.
Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).
Chih-Hung Hsu,Shan Lu,Alexander R. Abbas,Yinghui Guan,Andrew X. Zhu,Alexey Aleshin,Kyung-Hun Lee,Michael Sangmin Lee,Amit Mahipal,Baek-Yeol Ryoo,Beiying Ding,Jessica Spahn,Wendy Verret,Aiwu Ruth He,Yulei Wang +14 more
TL;DR: CTDNA has emerged as a promising biomarker for noninvasive monitoring of treatment response and disease progression in many tumor types, but the clinical use of ctDNA in patien...
29
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Thomas Powles,Michael B. Atkins,Bernard Escudier,Robert J. Motzer,Brian I. Rini,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,Mario Sznol,John D. Hainsworth,Walter M. Stadler,Thomas E. Hutson,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Toni K. Choueiri,James A. Reeves,Allen Lee Cohn,Beiying Ding,Ning Leng,Kenji Hashimoto,Mahrukh Huseni,Christina Schiff,David F. McDermott +23 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of atezolizumab+bevacizumaba using a randomized, open-label, phase 2 study with metastatic clear cell renal cancer (mRCC).
28
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K. Pal,David F. McDermott,Michael B. Atkins,Bernard Escudier,Brian I. Rini,Robert J. Motzer,Lawrence Fong,Richard W. Joseph,Stéphane Oudard,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Elaine T. Lam,Toni K. Choueiri,Beiying Ding,Caroleen Quach,Kenji Hashimoto,Christina Schiff,Elisabeth Piault-Louis,Thomas Powles +19 more
TL;DR: The phase 2 IMmotion150 study showed improved progression‐free survival with atezolizumab plus bevacizumAB vs sunitinib in patients with programmed death‐ligand 1 (PD‐L1)+ tumours and suggested activity of atezoledzumab monotherapy in previously untreated metastatic renal cell carcinoma (mRCC).
21